Low-Dose rituximab shows promise for Hard-to-Treat ITP patients
NCT ID NCT01719692
First seen Feb 18, 2026 · Last updated May 07, 2026 · Updated 9 times
Summary
This study tested two low-dose rituximab schedules in 100 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The goal was to see if these regimens could safely raise platelet counts and reduce bleeding. Participants had failed or relapsed on standard steroid therapy. The trial compared weekly low doses versus a single higher dose to find a better-tolerated option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of Blood disease
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.